Table 1 Clinical characteristics and comprehensive geriatric assessment according to the risk of CHA2DS2-VASc score.
Variables | Total (N = 117) | Intermediate risk of CHA2DS2-VASc (n = 13) | High risk of CHA2DS2-VASc† (n = 104) | p value |
|---|---|---|---|---|
Demographics | ||||
Age (year) | 78 (74–82) | 72 (70.5–74) | 78.5 (76–83) | < 0.001 |
Sex, female (%) | 53 (45.3%) | 6 (46.2%) | 47 (45.2%) | 0.948 |
BMI, kg/m2 | 25.2 (23.0–27.1) | 25.2 (22.2–27.4) | 25.1 (23.0–27.0) | 0.752 |
Medication and risk stratification | ||||
Antiplatelet use | 57 (48.7%) | 9 (69.2%) | 48 (46.2%) | 0.147 |
Anticoagulation use | 65 (55.6%) | 4 (30.8%) | 61 (58.7%) | 0.076 |
Elevated HAS-BLED risk (≥ 3) | 29 (24.8%) | 1 (7.7%) | 28 (26.9%) | 0.181 |
Comprehensive geriatric assessment | ||||
CCI | 1 (0–2) | 0 (0–1.5) | 1 (0–2) | 0.048 |
ADL dependency | 13 (11.1%) | 0 (0%) | 13 (12.5%) | NA |
IADL dependency | 21 (17.9%) | 0 (0%) | 21 (20.2%) | NA |
TUGT‡ | 13 (10–14) | 10 (9–12) | 13 (11–14.75) | 0.004 |
Gait speed§ | 0.98 (0.79–1.17) | 1.23 (0.96–1.41) | 0.97 (0.75–1.14) | 0.007 |
Grip strength | 24.5 (18.9–30.8) | 30.1 (22.1–39.6) | 24.1 (18.4–30.5) | 0.120 |
MMSE-KC | 26 (22–28) | 28 (25.5–28) | 26 (22–28) | 0.161 |
SGDS-K¶ | 3 (1–7) | 2 (0–2.5) | 3 (1–7.5) | 0.025 |
MNA | 26 (23–27) | 28 (26.3–28) | 25.5 (22.5–27) | 0.001 |
Polypharmacy (≥ 5 drugs) | 86 (73.5%) | 4 (30.8%) | 82 (48.8%) | 0.001 |
Frailty index | 0.06 (0–0.17) | 0 (0–0.06) | 0.06 (0–0.19) | 0.007 |